OBJECTIVES: Subthalamic nucleus (STN) deep brain stimulation (DBS) is an effective intervention in advanced Parkinson's disease (PD), but its efficacy and safety in early PD are unknown. We are conducting a randomized pilot trial investigating DBS in early PD. This report describes one participant who received bilateral STN-DBS. MATERIALS AND METHODS: Thirty subjects have been randomized to either optimal drug therapy (ODT) or DBS + ODT. Microelectrode recordings from the STN and substantia nigra are collected at implantation. The Unified Parkinson's Disease Rating Scale Motor Subscale (UPDRS-III) is administered in the ON and OFF states semi-annually and neuropsychological function and quality of life are assessed annually. We describe a 54-year-old man with a two-year history of PD who was randomized to DBS + ODT and followed for two years. RESULTS: The subject showed a lower STN to substantia nigra ratio of neuronal activity than advanced PD patients, and higher firing rate than non-PD patients. The subject's total UPDRS and UPDRS-III scores improved during the two-year follow-up, while his OFF UPDRS-III score and levodopa equivalent daily dose increased. Quality of life, verbal fluency, and verbal learning improved. He did not experience any serious adverse events. CONCLUSIONS: This report details the first successful application of bilateral STN-DBS for early-stage PD during a clinical trial.
OBJECTIVES: Subthalamic nucleus (STN) deep brain stimulation (DBS) is an effective intervention in advanced Parkinson's disease (PD), but its efficacy and safety in early PD are unknown. We are conducting a randomized pilot trial investigating DBS in early PD. This report describes one participant who received bilateral STN-DBS. MATERIALS AND METHODS: Thirty subjects have been randomized to either optimal drug therapy (ODT) or DBS + ODT. Microelectrode recordings from the STN and substantia nigra are collected at implantation. The Unified Parkinson's Disease Rating Scale Motor Subscale (UPDRS-III) is administered in the ON and OFF states semi-annually and neuropsychological function and quality of life are assessed annually. We describe a 54-year-old man with a two-year history of PD who was randomized to DBS + ODT and followed for two years. RESULTS: The subject showed a lower STN to substantia nigra ratio of neuronal activity than advanced PD patients, and higher firing rate than non-PD patients. The subject's total UPDRS and UPDRS-III scores improved during the two-year follow-up, while his OFF UPDRS-III score and levodopa equivalent daily dose increased. Quality of life, verbal fluency, and verbal learning improved. He did not experience any serious adverse events. CONCLUSIONS: This report details the first successful application of bilateral STN-DBS for early-stage PD during a clinical trial.
Authors: P David Charles; Bimal B Padaliya; William J Newman; Chandler E Gill; Cassondra D Covington; John Y Fang; Stephanie A So; Michael G Tramontana; Peter E Konrad; Thomas L Davis Journal: Parkinsonism Relat Disord Date: 2004-12 Impact factor: 4.891
Authors: Günther Deuschl; Carmen Schade-Brittinger; Paul Krack; Jens Volkmann; Helmut Schäfer; Kai Bötzel; Christine Daniels; Angela Deutschländer; Ulrich Dillmann; Wilhelm Eisner; Doreen Gruber; Wolfgang Hamel; Jan Herzog; Rüdiger Hilker; Stephan Klebe; Manja Kloss; Jan Koy; Martin Krause; Andreas Kupsch; Delia Lorenz; Stefan Lorenzl; H Maximilian Mehdorn; Jean Richard Moringlane; Wolfgang Oertel; Marcus O Pinsker; Heinz Reichmann; Alexander Reuss; Gerd-Helge Schneider; Alfons Schnitzler; Ulrich Steude; Volker Sturm; Lars Timmermann; Volker Tronnier; Thomas Trottenberg; Lars Wojtecki; Elisabeth Wolf; Werner Poewe; Jürgen Voges Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: J Michael Fitzpatrick; Peter E Konrad; Chris Nickele; Ebru Cetinkaya; Chris Kao Journal: Stereotact Funct Neurosurg Date: 2005-04-08 Impact factor: 1.875
Authors: R A Hauser; J Friedlander; T A Zesiewicz; C H Adler; L C Seeberger; C F O'Brien; E S Molho; S A Factor Journal: Clin Neuropharmacol Date: 2000 Mar-Apr Impact factor: 1.592
Authors: Peter E Konrad; Joseph S Neimat; Hong Yu; Chris C Kao; Michael S Remple; Pierre-François D'Haese; Benoit M Dawant Journal: Stereotact Funct Neurosurg Date: 2010-12-15 Impact factor: 1.875
Authors: F Steigerwald; M Pötter; J Herzog; M Pinsker; F Kopper; H Mehdorn; G Deuschl; J Volkmann Journal: J Neurophysiol Date: 2008-08-13 Impact factor: 2.714
Authors: Mallory L Hacker; Maxim Turchan; Lauren E Heusinkveld; Amanda D Currie; Sarah H Millan; Anna L Molinari; Peter E Konrad; Thomas L Davis; Fenna T Phibbs; Peter Hedera; Kevin R Cannard; Li Wang; David Charles Journal: Neurology Date: 2020-06-29 Impact factor: 11.800
Authors: D Luke Fischer; Timothy J Collier; Allyson Cole-Strauss; Susan L Wohlgenant; Jack W Lipton; Kathy Steece-Collier; Fredric P Manfredsson; Christopher J Kemp; Caryl E Sortwell Journal: PLoS One Date: 2015-07-29 Impact factor: 3.240